Grants paid by The Nancy Taylor Foundation for Chronic Diseases Inc
EIN 26-2343375 · Tulsa, OK · Form 990-PF, Part XV · NTEE H12
The Nancy Taylor Foundation for Chronic Diseases Inc of Tulsa, OK (EIN 26-2343375) reported 24 grants paid totaling $2,609,670 to 7 recipients in tax years 2018–2024, on Form 990-PF, Part XV. It also reported $108,000 approved for future payment, which is listed separately and not included in the total. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$2,609,670
24 grants
Recipients
7
distinct organizations
Tax years
2018–2024
5 filings in the corpus
Approved for future payment
$108,000
1 commitment · not included in grants paid
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 9 | $972,000 | — |
| 2020 | 3 | $424,000 | — |
| 2022 | 5 | $636,000 | — |
| 2023 | 3 | $233,000 | — |
| 2024 | 4 | $344,670 | $108,000 |
Top recipients
The 7 recipients receiving the most from The Nancy Taylor Foundation for Chronic Diseases Inc, by grants paid, out of 7 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Yale University | U | New Haven, CT | 11 | $1,187,070 | 2024 |
| University of Pittsburgh 25-0965591 | C | Pittsburgh, PA | 5 | $620,000 | 2023 |
| The Children's Hospital of Philadel 23-1352166 | C | Philadelphia, PA | 3 | $324,000 | 2024 |
| University of Pittsburgh | U | Pittsburg, PA | 2 | $216,000 | 2018 |
| The Nemours Foundation | U | Wilmington, DE | 1 | $129,600 | 2024 |
| Washington University 52-1538367 | B | St Louis, MO | 1 | $108,000 | 2018 |
| National Cfids Foundation 04-3350621 | C | Needham, MA | 1 | $25,000 | 2023 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 25 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | The Nemours Foundation Wilmington, DE | U | $129,600 | paid | "EXAMINING THE ROLE OF FIBROBLAST-LIKE SYNOVIOCYTES IN JUVENILE IDIOPATHIC ARTHRITIS" BY ANNE MARIE BRESCIA, M.D. | 202543149349102319 |
| 2024 | University of Pittsburgh Pittsburgh, PA | C | $108,000 | approved, future | "SERUM CYTOKINE PROFILES IN LOCALIZED SCLERODERMA" BY KATHRYN TOROK, MD | 202543149349102319 |
| 2024 | Children's Hospital of Philadelphia Philadelphia, PA | B | $108,000 | paid | PROJECT TO INVESTIGATE POTENTIAL MECHANISMS BY WHICH NRF2 REPRESSES IL 12B WITH A POTENTIAL GENOME-WIDE EFFECT AND THE ROLE OF NRF2-NFIL3 INTERACTIONS IN IL 12B REPRESSION BY NRF2 BY EDWARD M. BEHRENS, M.D. | 202543149349102319 |
| 2024 | Yale University New Haven, CT | U | $108,000 | paid | "NOVEL APPROACHES TO TREATING CHRONIC DISEASES" BY STEPHEN WAXMAN, M.D PH.D. | 202543149349102319 |
| 2024 | Yale University New Haven, CT | U | -$930 | paid | RETURN OF UNSPENT FUNDS | 202543149349102319 |
| 2023 | Yale University New Haven, CT | U | $108,000 | paid | TARGETED NEUROFEEDBACK: A NOVEL NONPHARMOLOGICAL TREATMENT FOR OCD BY DR. CHRIS PITTENGER | 202423209349104217 |
| 2023 | University of Pittsburgh Pittsburgh, PA | C | $100,000 | paid | CELLULAR PHENOTYPE CONTRIBUTING TO IMMUNE DYSREGULATION IN LOCALIZED SCLERODERMA BY KATHRYN TOROK, M.D. | 202423209349104217 |
| 2023 | National Cfids Foundation Needham, MA | C | $25,000 | paid | TO SUPPORT RESEARCH | 202423209349104217 |
| 2022 | University of Pittsburgh Pittsburgh, PA | C | $212,000 | paid | TRANSLATIONAL EVALUATION OF THE PATHOGENICITY OF DNT CELLS IN RHEUMATIC DISEASES OF CHILDREN AND IN A MOUSE MODEL OF EARLY EARLY-ONSET SYNOVITIS BY ABBE N. DE VALLEJO, PH.D. | 202302689349100765 |
| 2022 | Children's Hospital of Philadelphia Philadelphia, PA | B | $108,000 | paid | MECHANISMS OF MMF/HO-1 REGULATION OF HYPERINFLAMMATION BY DR. BEHREN. | 202302689349100765 |
| 2022 | Yale University New Haven, CT | U | $108,000 | paid | NOVEL APPROACHES TO THE STUDY OF PAIN AND TARGETING OF CHRONIC PAIN BY DR. WAXMAN. | 202302689349100765 |
| 2022 | Yale University New Haven, CT | U | $108,000 | paid | TARGETED NEUROFEEDBACK: A NOVEL NONPHARMOLOGICAL TREATMENT FOR OCD BY DR. CHRIS PITTENGER | 202302689349100765 |
| 2022 | University of Pittsburgh Pittsburgh, PA | C | $100,000 | paid | CELLULAR PHENOTYPE CONTRIBUTING TO IMMUNE DYSREGULATION IN LOCALIZED SCLERODERMA BY KATHRYN TOROK, M.D. | 202302689349100765 |
| 2020 | Yale University New Haven, CT | U | $216,000 | paid | TARGETED NEUROFEEDBACK: A NOVEL NONPHARMACOLOGICAL TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER BY CHRISTOPHER PITTENGER, M.D., PH.D. | 202102509349101100 |
| 2020 | University of Pittsburgh Pittsburgh, PA | C | $108,000 | paid | TRANSLATIONAL EVALUATION OF THE PATHOGENICITY OF DNT CELLS IN RHEUMATIC DISEASES OF CHILDREN AND IN A MOUSE MODEL OF EARLY EARLY-ONSET SYNOVITIS BY ABBE N. DE VALLEJO, PH.D. | 202102509349101100 |
| 2020 | University of Pittsburgh Pittsburgh, PA | C | $100,000 | paid | CELLULAR PHENOTYPE CONTRIBUTING TO IMMUNE DYSREGULATION IN LOCALIZED SCLERODERMA BY KATHRYN TOROK, M.D. | 202102509349101100 |
| 2018 | Yale University New Haven, CT | U | $108,000 | paid | DIAGNOSTIC STABILITY AND EARLY CHILDHOOD PREDICTORS OF OUTCOME IN AUTISM SPECTRUM DISORDERS BY FRED VOLKMAR, M.D. | 201931349349102273 |
| 2018 | University of Pittsburgh Pittsburg, PA | U | $108,000 | paid | SERUM CYTOKINE PROFILES IN LOCALIZED SCLERODERMA BY KATHRYN TOROK, M.D. | 201931349349102273 |
| 2018 | The Children's Hospital of Philadel Philadelphia, PA | C | $108,000 | paid | IL-33 SIGNALING IN FHL BY EDWARD M. BEHRENS, M.D. | 201931349349102273 |
| 2018 | Yale University New Haven, CT | U | $108,000 | paid | VIRAL-MEDICATED APPROACH FOR THE STUDY OF PAIN AND SPASTICITY BY STEPHAN WAXMAN, M.D. PH.D | 201931349349102273 |
| 2018 | Yale University New Haven, CT | U | $108,000 | paid | TARGETED NEUROFEEDBACK: A NOVEL NONPHARMACOLOGICAL TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER BY CHRISTOPHER PITTENGER, M.D., PH.D. | 201931349349102273 |
| 2018 | Yale University New Haven, CT | U | $108,000 | paid | VALIDATION OF METHODS TO IMAGE KETAMINE-INDUCED CHANGES IN THE HUMAN BRAIN BY IRINA ESTERLIS, PH.D. | 201931349349102273 |
| 2018 | University of Pittsburgh Pittsburg, PA | U | $108,000 | paid | MALADAPTIVE DOUBLE NEGATIVE T CELLS IN JUVENILE IDIOPATHIC ARTHRITIS BY ABBE N. DE VALLEJO, PH. D | 201931349349102273 |
| 2018 | Yale University New Haven, CT | U | $108,000 | paid | HUMAN GENETIC VARIATION IN CYTOKINE SIGNALING PATHWAYS AND SUSCEPTIBILITY TO AUTOIMMUNE DISEASE BY DAVID HAFLER, M.D. | 201931349349102273 |
| 2018 | Washington University St Louis, MO | B | $108,000 | paid | DESIGNER STEM CELLS FOR TREATING CHRONIC DISEASES BY FARSHID GUILAK, PH.D. | 201931349349102273 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990PF | 2024 | 2024-12-31 | not stated | 2024v5.2 | 202543149349102319 |
| 990PF | 2023 | 2023-12-31 | not stated | 2023v5.1 | 202423209349104217 |
| 990PF | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202302689349100765 |
| 990PF | 2020 | 2020-12-31 | not stated | 2020v4.1 | 202102509349101100 |
| 990PF | 2018 | 2018-12-31 | not stated | 2018v3.1 | 201931349349102273 |
Derived from IRS Form 990-PF e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/262343375.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.